Femasys Q2 Sales Fall 19% to $332K; Cash at $1.4M Before $30M Placement
FEMY is trading near its 52-week low of $2.19 (6.8% above the low).
Summary
Femasys reported Q2 2026 sales of $331,827, down 18.9% year-over-year, with a net loss of $4.47M. Cash was $1.4M at quarter-end, but a $30M private placement closed after June 30 provides funding for commercial and clinical programs.
Key Events · Earnings and Guidance · FEMY
-
Q2 Sales Decline 18.9%
Sales fell to $331,827 from $409,268 in Q2 2025, primarily due to lower FemVue sales.
-
Net Loss Narrows Slightly
Net loss was $4.47M ($1.33/share) vs $4.59M ($3.18/share) a year ago, helped by non-cash gains on warrant and conversion option liabilities.
-
Cash Position Critical
Cash and equivalents were $1.4M at June 30, 2026, down from $9.3M at year-end 2025, but a $30M private placement closed after quarter-end.
-
New Corporate Milestones
CE Mark approval for FemHSG Catheter, partnership with AMI Technologies for Israel, and appointment of John Canning as COO.
Analysis · FEMY · Industrial Applications And Services
Femasys reported Q2 sales of $331,827, down 18.9% year-over-year, while net loss narrowed slightly to $4.47M. The balance sheet shows only $1.4M in cash as of June 30, 2026, but the company completed a $30M private placement after quarter-end, providing runway. The filing also details new corporate milestones including CE Mark approval for FemHSG, an Israel partnership, and a new COO appointment.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.6% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FEMY was trading at $2.34 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.9M. The 52-week trading range was $2.19 to $22.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.